These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 22217686)

  • 1. [Novel oral anticancer drugs: a review of adverse drug reactions, interactions and patient adherence].
    Bartal A; Mátrai Z; Szucs A; Belinszkaja G; Langmár Z; Rosta A
    Orv Hetil; 2012 Jan; 153(2):66-78. PubMed ID: 22217686
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral targeted therapies: managing drug interactions, enhancing adherence and optimizing medication safety in lymphoma patients.
    Liewer S; Huddleston AN
    Expert Rev Anticancer Ther; 2015 Apr; 15(4):453-64. PubMed ID: 25683755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug interactions in metastatic breast cancer.
    Tyler T
    J Oncol Pharm Pract; 2011 Sep; 17(3):236-45. PubMed ID: 20861179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient adherence to oral anticancer drugs: an emerging issue in modern oncology.
    Foulon V; Schöffski P; Wolter P
    Acta Clin Belg; 2011; 66(2):85-96. PubMed ID: 21630604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adherence to oral cancer therapies: nursing interventions.
    Winkeljohn D
    Clin J Oncol Nurs; 2010 Aug; 14(4):461-6. PubMed ID: 20682501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral administration of antineoplastic agents: the challenges for healthcare professionals.
    Tadic D; Spasojevic IB; Tomasevic ZI; Dejanovic SD
    J BUON; 2015; 20(3):690-8. PubMed ID: 26214619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral Anticancer Therapy: Management of Drug Interactions.
    Rogala BG; Charpentier MM; Nguyen MK; Landolf KM; Hamad L; Gaertner KM
    J Oncol Pract; 2019 Feb; 15(2):81-90. PubMed ID: 30763198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
    Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
    Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer oral therapy: emerging related issues.
    Banna GL; Collovà E; Gebbia V; Lipari H; Giuffrida P; Cavallaro S; Condorelli R; Buscarino C; Tralongo P; Ferraù F
    Cancer Treat Rev; 2010 Dec; 36(8):595-605. PubMed ID: 20570443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guiding pharmacist clinical interviews: a safety tool to support the education of patients treated with oral antineoplastic agents.
    Ribed A; Escudero-Vilaplana V; Romero-Jimenez RM; Iglesias-Peinado I; Herranz-Alonso A; Sanjurjo-Saez M
    Expert Opin Drug Saf; 2016; 15(4):427-35. PubMed ID: 26854363
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review on adherence management in patients on oral cancer therapies.
    Wood L
    Eur J Oncol Nurs; 2012 Sep; 16(4):432-8. PubMed ID: 22051845
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents.
    Gebbia V; Bellavia G; Ferraù F; Valerio MR
    Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S49-59. PubMed ID: 22149481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Large-scale automatic extraction of side effects associated with targeted anticancer drugs from full-text oncological articles.
    Xu R; Wang Q
    J Biomed Inform; 2015 Jun; 55():64-72. PubMed ID: 25817969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome Assessments and Cost Avoidance of an Oral Chemotherapy Management Clinic.
    Wong SF; Bounthavong M; Nguyen CP; Chen T
    J Natl Compr Canc Netw; 2016 Mar; 14(3):279-85. PubMed ID: 26957614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence and patients' experiences with the use of oral anticancer agents.
    Timmers L; Boons CC; Kropff F; van de Ven PM; Swart EL; Smit EF; Zweegman S; Kroep JR; Timmer-Bonte JN; Boven E; Hugtenburg JG
    Acta Oncol; 2014 Feb; 53(2):259-67. PubMed ID: 24266637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral Anticancer Medication Adherence, Toxicity Reporting, and Counseling: A Study Comparing Health Care Providers and Patients.
    Gandhi S; Day L; Paramsothy T; Giotis A; Ford M; Boudreau A; Pasetka M
    J Oncol Pract; 2015 Nov; 11(6):498-504. PubMed ID: 26395564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New Oral Anti-Cancer Drugs and Medication Safety.
    Schlichtig K; Dürr P; Dörje F; Fromm MF
    Dtsch Arztebl Int; 2019 Nov; 116(46):775-782. PubMed ID: 31920193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists.
    Regnier Denois V; Poirson J; Nourissat A; Jacquin JP; Guastalla JP; Chauvin F
    Eur J Cancer Care (Engl); 2011 Jul; 20(4):520-7. PubMed ID: 20649809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence to oral endocrine treatments in women with breast cancer: can it be improved?
    Doggrell SA
    Breast Cancer Res Treat; 2011 Sep; 129(2):299-308. PubMed ID: 21594663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are patients on oral chemotherapy in your practice setting safe?
    Moody M; Jackowski J
    Clin J Oncol Nurs; 2010 Jun; 14(3):339-46. PubMed ID: 20529795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.